Shares: no-invasive diagnostics will be the future growth aspect

Liver cancer and cirrhosis are a disease that makes people nervous. Chronic diseases such as hepatitis B can lead to cirrhosis or liver cancer through the process of hepatic fibrosis.　　Block the process of liver fibrosis, so as to prevent liver cancer, liver cirrhosis, this is the idea of the stock products. The core business of the shares is the diagnosis and treatment of liver fibrosis. Wang Guanji, chairman of the company, said on the interactive platform: "Liver fibrosis is due to chronic liver disease, from the current statistical data, the number of chronic liver disease is not a significant decline in the trend." In the long run, hepatitis B patients will be reduced, but patients with fatty liver will increase.　　According to the Japanese Securities Report statistics, 2008 China's liver disease treatment market overall sales of 12.6 billion yuan, an increase of 11%. Now the company production of compound turtle soft liver tablets in the national market share for the first.　　It is understood that soft liver film is the national SFDA approved the first professional treatment of liver fibrosis drugs.　　Soft liver film has now covered 29 major cities nationwide sales, the company said the focus is now to cover other small and medium-sized cities market. At present, the performance of the shares of the soft liver film has a greater reliance on sales. The company's prospectus shows that the sales of soft liver films accounted for 87.79%, 93.66%, 92.85% and 96.12% of the company's combined sales revenue in the first half of the 2006-2009 year.　　The growing sales of soft liver films have also boosted the company's performance. Quarterly reports show that the 2010-year first quarter of the business revenue to achieve 36.55 million yuan, an increase of 21.5%.　　Realized attributable to the parent company net profit of 9.18 million, an increase of 197.4%. However, according to the Japanese Securities report, anti-liver fibrosis products belonging to a subdivision of Chinese medicine products, 2008 overall drug sales income of 570 million yuan, the market size is small.　　Overall, in the area of liver disease treatment, Western medicine still occupies an absolute advantage, the market share of 65%, and nearly three years of growth trend, the company can be the market bigger, waiting to see.　　The reporter asked the company about this question, but did not get a positive answer. In addition, soft liver tablet is a Chinese medicine tablet, its raw materials have blindly cordyceps sinensis market price fluctuations are also famous. The cost of cordyceps sinensis is 70% of the cost of producing soft liver slices. In a report on the securities of Japan, the company's shares in 2009 have hoarded 4 tons of cordyceps sinensis at the time, enough to cover 2010 years of production.　　In addition, the reporter noted that the shares of the company has begun to use a caterpillar fungus called cordyceps sinensis (blog) to replace the experiment. According to the company's chairman on the interactive platform to answer investor questions: "The company has carried out a clinical trial of cordyceps sinensis to replace cordyceps sinensis, and in the preliminary test has achieved positive results, is expected to direct clinical trials in the human body will begin in the second half of this year." "In addition to the soft liver film, the liver fibrosis on line diagnosis System (FSTM) based on the liver fibrosis non-invasive Diagnostic Technology Service will be the company's next three years a new profit growth point." The advantage of noninvasive diagnosis is that the traditional liver puncture therapy can solve the humanThe huge damage and reduce the cost of checking. The company said that Fstm will complete the system development and on-line at the end of this year, and enter the promotion stage.　　The reporter also noted that the shares of the fstm has now been launched on its official website of the relevant sales staff recruitment. The company expects the sales revenue of fstm to reach 49.71 million yuan in 2010.　　The project's profit model is to cooperate with the hospital to provide ultrasonic diagnostic equipment and technical support services, while cooperating with the sale of therapeutic drugs, so the promotion of this treatment will also promote the company's main products soft liver film sales.　　Hengtai Securities Forecast, the company's Fstm project in 2010 will achieve revenue of 38.1 million yuan, is 2009 the project Income 7.4 times times, while the FSTM project accounted for the proportion of total revenue from 2009 2.85%, promoted to 2010 14.29%.　　Guotai analysts believe that under the Fstm project, the company is expected to maintain its annual growth rate of more than 20% in the next 3 years. Risk tip: 1. No-invasive diagnostic system to promote the risk of not up to expectations; 2. The risk of the price increase of compound soft liver tablets of soft-shelled turtle.